Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 in mild to moderate Alzheimer's disease
NCT02244541Phase 2Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Dec 2014
- Primary completion
- Nov 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of blarcamesine in Alzheimer's disease (AD), sponsored by Anavex Life Sciences Corp.. Started Dec 2014; status: completed.
02
Drugs
blarcamesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02244541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02244541.